Will Waterfield, PhD Independent Consultant

Will Waterfield, PhD, began his professional career at Lederle Laboratories (Pearl River, NY) in the Recombinant Oral Polio Vaccine Group he later led the Vero Cell based Inactivated Polio Vaccine (IPV) Commercial Manufacturing. Tetanus, Diphtheria, PNU-IMUNE, Tuberculosis Tines, Pneumo-Conjugate and Glassware/Media Operations GMP operations were added to his responsibilities. After the IPV project was cancelled, Dr. Waterfield was named as project lead of the partial demolition of the IPV facility, design, construction, start-up, commissioning and licensure of the pneumococcal conjugate vaccine (Prevenar) facility occupying IPV facility footprint. He stayed on to direct Prevenar Polysaccharide Commercial Operations until 2003. He departed commercial vaccine operations and created the Manufacturing Science and Technology (MSAT). MSAT are wet lab/pilot plant development laboratories dedicated to support commercial operations. From 2012 until his departure in 2018, he focused on evaluating and implementing new pharmaceutical technology and created a business process to identify and implement best in class and next in class technology. NextGeneration Manufacturing Technologies (NextGen) reaches across all of Pfizer. NextGen conducts interviews of process owners and searches the technical solutions landscape addressing the needs of Commercial Operations as well as monitors project progress against milestones, advances timelines and cancels project not meeting endpoints.